TP53 and ovarian carcinoma: Moreover, our cell-based assays provide evidence that extracellularly released p53 aggregates interfere with the cytotoxic activity of cisplatin, a platinum-based chemotherapeutic agent often used in ovarian cancers (30), in the recipient cells.